약물관련골괴사 (Medication-Related Osteonecrosis of the jaw): 2014 update of BRONJ
MRONJ (Medication-Related Osteonecrosis of the jaw): 2014 update of BRONJ (Bisphosphonate-related Osteonecrosis of the jaw)
유태민,
소속 상세정보
유태민 ( You Tae-Min ) - 단국대학교 치과대학 통합진료과학교실
KMID : 1146620140030020057
Abstract
Bisphosphonate-related osteonecrosis of the jaw (BRONJ) adversely affects the quality of life, producing significant morbidity. Recently, since the number of osteonecrosis cases involving the maxilla and mandible associated with other antiresorptive (denosumab) and antiangiogenic therapies are growing, the Special Committee recommends changing the nomenclature of bisphosphonate-related osteonecrosis of the jaw (BRONJ) to the medication-related osteonecrosis of the jaw (MRONJ). Strategies for management of patients with, or at risk for, MRONJ were set forth in the American Association of Oral and Maxillofacial Surgeons (AAOMS) updated Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaws and approved by the Board of Trustees in 2009. Because it vitally important that this information be disseminated to other relevant health care professionals and dental professional, I would like to introduce 2014 MRONJ postion paper.
키워드
Osteonecrosis; Antiresorptive; Antiangiogenic; MRONJ
원문 및 링크아웃 정보
등재저널 정보